Neurocrine Biosciences chief legal officer sells $254,991 in stock

SAN DIEGO—Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently disclosed stock transactions in a filing with the Securities and Exchange Commission. On February 13, Lippoldt sold a total of 2,184 shares of the company's common stock in two separate transactions. The shares were sold at an average price range of $115.98 to $118.38, amounting to a total of $254,991. The transactions come as the stock trades near its 52-week low of $110.95, with InvestingPro analysis indicating the stock is currently undervalued.

The filing also reported that Lippoldt acquired 4,100 shares through option exercises on the same day, though these transactions did not involve any cash exchange. Following these transactions, Lippoldt holds 43,405 shares of Neurocrine Biosciences. The company maintains strong financial health with a current ratio of 3.4x and operates with moderate debt levels, according to InvestingPro data.

These transactions were executed under pre-established trading plans, as indicated by the company’s adherence to Rule 10b5-1, which restricts modification of the trading plan after its adoption.

In other recent news, Neurocrine Biosciences has been the focus of several analyst reports. Deutsche Bank (ETR:DBKGn) initiated coverage on Neurocrine Biosciences, setting a price target of $138 and assigning a Hold rating. The bank's analyst emphasized the importance of the company's Ingrezza treatment for TD/HD chorea and Crensessity for CAH in its valuation.

UBS analyst Ashwani Verma adjusted the price target for Neurocrine Biosciences to $154 from the previous $176, while maintaining a Buy rating. The adjustment followed lower-than-anticipated guidance for Ingrezza and the lack of substantial updates on Crenessity. At the same time, Guggenheim maintained a Buy rating but lowered the price target to $163 from $165 after the company's fourth-quarter sales report showed Ingrezza sales slightly below consensus estimates.

H.C. Wainwright analyst Andrew Fein adjusted the price target for Neurocrine Biosciences to $185 from the previous $190, maintaining a Buy rating. This was prompted by the lower-than-expected full-year 2025 Ingrezza revenue guidance. Despite these adjustments, analysts from different firms continue to express confidence in Neurocrine Biosciences' potential for future gains.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.